Indivior enjoys a strong recovery as it targets primary US listing
Shares in Indivior (INDV) are up 36% year-to-date. The latest catalyst for the opioid-use disorder treatment specialist came in the form of 2023 sales and profit towards the top end of expectations and guidance for stronger than forecast profit growth in 2024 (22 February).Also giving the shares a boost was the news the company plans to move its primary stock exchange listing to the US where it ma